Budd-Chiari syndrome and its associated hepatocellular carcinoma: Clinical risk factors and potential immunotherapeutic benefit analysis

• DOI: 10.3389/fonc.2022.1075685
• Publication Date: 2022-12-08T14:55:40Z
• Authors: Kang-Shuai Li; Sen Guo; Yu-Xin Chen; Zong-Li Zhang
• Keywords: Budd–Chiari syndrome

Hepatocellular carcinoma (HCC) is a well-described complication of Budd-Chiari syndrome (BCS). However, the risk factors BCS in developing HCC and clinical characteristics imaging features BCS-associated still to be determined.Data from 113 consecutive patients with primary Qilu hospital were retrospectively studied. The 12 associated also analyzed. Chi-square analysis was performed analyze differences characteristics. treatment regime CT illustrated.113 admitted our between January 2009 June 2016 diagnosis enrolled. 10.6% (12/113) diagnosed HCC. mainly male gender an average age 49.2 years. Symptom duration longer than one year exhibited decreased serum ALT AST increased ascites ratio. presented IVC block stricture hepatic venous outflow tract. Patients older showed elevated total bilirubin. Most nodules located right posterior lobe heterogeneous enhancement during arterial phase washout delayed phase.The results indicate that tract seem irregular on phase.